R&D Boosting clinical trial productivity to prove Eroom wrong According to Eroom’s law, drug discovery becomes slower and costlier over time. And the data are, at least in part, bearing that out.
News In shock move, EU panel rejects Alzheimer's drug Leqembi The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.